아토피 피부염이 있는 만 3개월 이상 24개월 미만 참가자를 대상으로 Tapinarof 크림 1%의 안전성과 유효성을 조사하는 연구 (Adoring)
아토피 피부염이 있는 3개월 이상 ~ 24개월 미만의 소아 참가자를 대상으로 타피나로프 크림 1%의 안전성과 효능을 조사하기 위한 무작위 배정, 이중 맹검, 대조군(1기) 및 개방형(2기) 3상 연구
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 3단계
연락처 및 위치
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35209
- AllerVie Clinical Research
-
-
Arkansas
-
Bryant, Arkansas, 미국, 72022
- Dermatology Trial Associates
-
-
California
-
Los Angeles, California, 미국, 90045
- Dermatology Research Associates
-
Sacramento, California, 미국, 95815
- Integrative Skin Science and Research
-
San Diego, California, 미국, 92123
- Allergy and Asthma Medical Group and Research Center
-
Thousand Oaks, California, 미국, 91320
- Clinical Trials Research Institute
-
-
Colorado
-
Castle Rock, Colorado, 미국, 80109
- Clarity Dermatology
-
-
Florida
-
Boca Raton, Florida, 미국, 33486
- Skin Care Research, LLC.
-
Jacksonville, Florida, 미국, 32256
- APEX Clinical Trials
-
Wellington, Florida, 미국, 33449
- TruDerm Research
-
-
Georgia
-
Cumming, Georgia, 미국, 30040
- Cleaver Medical Group Dermatology, Inc
-
-
Idaho
-
Meridian, Idaho, 미국, 83646
- Ada West Research
-
-
Illinois
-
Skokie, Illinois, 미국, 60077
- Endeavor Health Clinical Trials Center
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46250
- Dawes Fretzin Clinical Research Group, LLC
-
Plainfield, Indiana, 미국, 46168
- The Indiana Clinical Trials Center, PC
-
-
Kentucky
-
Bowling Green, Kentucky, 미국, 42104
- Equity Medical, LLC
-
-
Maryland
-
Rockville, Maryland, 미국, 20850
- Lawrence J Green, MD LLC
-
-
Michigan
-
Auburn Hills, Michigan, 미국, 48326
- Oakland Hills Dermatology
-
-
Minnesota
-
New Brighton, Minnesota, 미국, 55112
- Minnesota Clinical Study Center
-
-
Mississippi
-
Ridgeland, Mississippi, 미국, 39157
- SKY Integrative Medical Center
-
-
Missouri
-
Saint Joseph, Missouri, 미국, 64506
- MediSearch Clinical Trials
-
-
Nevada
-
Reno, Nevada, 미국, 89509
- Skin Cancer and Dermatology Institute
-
-
New York
-
Kew Gardens, New York, 미국, 11415
- Forest Hills Dermatology Group
-
New York, New York, 미국, 10012
- Bobby Buka MD, PC
-
The Bronx, New York, 미국, 10455
- Equity Medical, LLC
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27516
- The University of North Carolina Dermatology and Skin Cancer Center
-
-
Ohio
-
Fairborn, Ohio, 미국, 45324
- Dermatologists of Central States, LLC
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73120
- Allergy Asthma and Clinical Research Center
-
-
Oregon
-
Portland, Oregon, 미국, 97210
- Oregon Dermatology and Research Center
-
Portland, Oregon, 미국, 97239
- Oregon Health & Science University
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- Medical University of South Carolina
-
North Charleston, South Carolina, 미국, 29420
- National Allergy and Asthma Research, LLC.
-
-
Texas
-
Bellaire, Texas, 미국, 77401
- The University of Texas Health Science Center at Houston
-
Dallas, Texas, 미국, 75230
- Dermatology Treatment and Research Center
-
Southlake, Texas, 미국, 76092
- Stryde Research - Epiphany Dermatology
-
-
Washington
-
Spokane, Washington, 미국, 99202
- Dermatology Specialists of Spokane
-
-
-
-
Alberta
-
Calgary, Alberta, 캐나다, T2J 7E1
- Dermatology Research Institute
-
Red Deer, Alberta, 캐나다, T4P 1K4
- CARe Clinic (Central Alberta Research Clinic)
-
-
British Columbia
-
Surrey, British Columbia, 캐나다, V3R 6A7
- Dr. Chih-Ho Hong Medical Inc.
-
-
Manitoba
-
Winnipeg, Manitoba, 캐나다, R3J 0S9
- Manitoba Allergy Research Inc.
-
-
Nova Scotia
-
Halifax, Nova Scotia, 캐나다, B3K 5R3
- Maritime Dermatology
-
-
Ontario
-
Burlington, Ontario, 캐나다, L7L 6W6
- Halton Pediatric Allergy
-
Hamilton, Ontario, 캐나다, L8S 1G5
- Triple A Lab Inc.
-
Niagara Falls, Ontario, 캐나다, L2H 1C4
- Allergy Research Canada Inc.
-
-
Saskatchewan
-
Regina, Saskatchewan, 캐나다, S4V 1R9
- Dr. Rachel Asiniwasis Medical Professional Corporation
-
Saskatoon, Saskatchewan, 캐나다, S7K 2C1
- Skinsense Medical Research
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Infants and toddlers born at term (≥37 weeks of gestational age) that are 3 months to <24 months of age at the Screening visit.
- Clinical diagnosis of atopic dermatitis (AD), AD covering >5% Body Surface Area (BSA) and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 2, 3 or 4
- Legal guardian or primary caregiver is willing and able to sign informed consent form before any study-related activities
- Legal guardian or primary caregiver is able and willing to adhere to protocol requirements
Exclusion Criteria:
- Significant neurological disorder or history of seizure
- Know clinically significant cardiac rhythm or cardiac disorder
- History of sudden infant death in a sibling
- Clinically significant chromosome abnormality
- History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation
- Diseases that could cause pruritic and/or sleep disruption
- Immunocompromised
- Current chronic or acute infection requiring treatment
- Use of prohibited medication(s) or procedure(s)
- Use of prohibited medications by breastfeeding mother if breastfeeding participant
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Tapinarof cream
Tapinarof cream, 1%, applied topically once daily |
Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.
다른 이름들:
|
|
위약 비교기: Vehicle cream
Vehicle cream is applied topically once daily for up to 8-weeks. |
Applied topically once daily to lesions on participant's skin during the Double-Blind period. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8
기간: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Percentage of participants who enter with or achieve have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement at least once during the Open-Label Period
기간: Baseline to the end of the Open-Label Period, up to 56 weeks.
|
The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint.. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. |
Baseline to the end of the Open-Label Period, up to 56 weeks.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of participants with ≥ 75% improvement in Eczema Area and Severity Index (EASI) Score from Baseline to Week 8.
기간: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the %BSA affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. A higher EASI score represents more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Mean change in percentage of total body surface area (%BSA) affected from Baseline to Week 8
기간: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
Assessment of %BSA is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% [10 handprints], upper extremities = 20% [20 handprints], trunk (including axillae and groin) = 30% [30 handprints], lower extremities, including buttocks, = 40% [40 handprints]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Percentage of participants with ≥ 90% improvement in Eczema Area and Severity Index (EASI) score from Baseline to Week 8
기간: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
Severity Index (EASI) score from Baseline to Week 8 Description: The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
기간: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
기간: Baseline to the end of the Open-Label Period, up to 56 weeks
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to the end of the Open-Label Period, up to 56 weeks
|
|
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
기간: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
|
|
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
기간: Baseline to the end of the Open-Label Period, up to 56 weeks.
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to the end of the Open-Label Period, up to 56 weeks.
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
기간: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
기간: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
기간: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
기간: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Clinical Lead Late-Stage Clinical Development, Organon and Co
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- OG0505-3104
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .